# GlycoMimetics
 (stock symbol: GLYC) Logo in transparent PNG and SVG formats

## GlycoMimetics
 Logo large

### GlycoMimetics
 Logo large Download PNG (29.74 KB)

![GlycoMimetics
 Logo large Download PNG (29.74 KB)](/img/orig/GLYC_BIG-a03a7c73.png)

### GlycoMimetics
 Logo large Download SVG (5.33 KB)

![GlycoMimetics
 Logo large Download SVG (5.33 KB)](/img/orig/GLYC_BIG-c60c8e8c.svg)

## GlycoMimetics
 Logo icon format

### GlycoMimetics
 Logo icon format Download PNG (70.71 KB)

![GlycoMimetics
 Logo icon format Download PNG (70.71 KB)](/img/orig/GLYC-ff6d7803.png)

### GlycoMimetics
 Logo icon format Download SVG (919 Bytes)

![GlycoMimetics
 Logo icon format Download SVG (919 Bytes)](/img/orig/GLYC-be216578.svg)

## GlycoMimetics
 Logo large for dark backgrounds

### GlycoMimetics
 Logo large for dark backgrounds Download PNG (29.41 KB)

![GlycoMimetics
 Logo large for dark backgrounds Download PNG (29.41 KB)](/img/orig/GLYC_BIG.D-9e7a4810.png)

### GlycoMimetics
 Logo large for dark backgrounds Download SVG (5.33 KB)

![GlycoMimetics
 Logo large for dark backgrounds Download SVG (5.33 KB)](/img/orig/GLYC_BIG.D-1e46a953.svg)

## GlycoMimetics
 Logo icon format for dark backgrounds

### GlycoMimetics
 Logo icon format for dark backgrounds Download PNG (69.39 KB)

![GlycoMimetics
 Logo icon format for dark backgrounds Download PNG (69.39 KB)](/img/orig/GLYC.D-668ff63f.png)

### GlycoMimetics
 Logo icon format for dark backgrounds Download SVG (916 Bytes)

![GlycoMimetics
 Logo icon format for dark backgrounds Download SVG (916 Bytes)](/img/orig/GLYC.D-51668101.svg)

## About GlycoMimetics


GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

1. Website domain: glycomimetics.com
2. Employees: 52
3. Marketcap: $89.94 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
